Sunzen Biotech Bhd (0148) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Sunzen Biotech Bhd (0148) has a cash flow conversion efficiency ratio of 0.027x as of September 2023. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (RM3.58 Million ≈ $897.56K USD) by net assets (RM134.42 Million ≈ $33.75 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See debt-free asset ratio of Sunzen Biotech Bhd to measure how much of total assets are equity-financed.
Sunzen Biotech Bhd - Cash Flow Conversion Efficiency Trend (2016–2023)
This chart illustrates how Sunzen Biotech Bhd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Sunzen Biotech Bhd cash earnings quality to evaluate the quality of earnings relative to operating cash generation.
Sunzen Biotech Bhd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Sunzen Biotech Bhd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Viscom AG
XETRA:V6C
|
0.051x |
|
eXoZymes, Inc.
NASDAQ:EXOZ
|
-0.998x |
|
Kristal Kola ve Mesrubat Sanayi Ticaret AS
IS:KRSTL
|
0.061x |
|
Li Cheng Enterprise Co Ltd
TW:4426
|
-0.022x |
|
Walkabout Resources Ltd
AU:WKT
|
-0.073x |
|
Sinher Technology Inc
TW:4999
|
0.012x |
|
Beijing JIAYU Door Window Curtain
SHE:300117
|
-0.023x |
|
PEH Wertpapier AG
F:PEH
|
0.048x |
Annual Cash Flow Conversion Efficiency for Sunzen Biotech Bhd (2016–2023)
The table below shows the annual cash flow conversion efficiency of Sunzen Biotech Bhd from 2016 to 2023. For the full company profile with market capitalisation and key ratios, see market value of Sunzen Biotech Bhd.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2023-12-31 | RM149.84 Million ≈ $37.62 Million |
RM819.39K ≈ $205.72K |
0.005x | +102.08% |
| 2022-12-31 | RM121.88 Million ≈ $30.60 Million |
RM-32.06 Million ≈ $-8.05 Million |
-0.263x | -89.88% |
| 2021-12-31 | RM118.10 Million ≈ $29.65 Million |
RM-16.36 Million ≈ $-4.11 Million |
-0.139x | -268.20% |
| 2020-12-31 | RM87.47 Million ≈ $21.96 Million |
RM7.20 Million ≈ $1.81 Million |
0.082x | +168.12% |
| 2019-12-31 | RM91.37 Million ≈ $22.94 Million |
RM-11.05 Million ≈ $-2.77 Million |
-0.121x | -217.88% |
| 2018-12-31 | RM106.94 Million ≈ $26.85 Million |
RM-4.07 Million ≈ $-1.02 Million |
-0.038x | -194.09% |
| 2017-12-31 | RM99.45 Million ≈ $24.97 Million |
RM4.02 Million ≈ $1.01 Million |
0.040x | +1434.55% |
| 2016-12-31 | RM97.23 Million ≈ $24.41 Million |
RM256.13K ≈ $64.31K |
0.003x | -- |
About Sunzen Biotech Bhd
Sunzen Group Berhad, an investment holding company, engages in the biotechnology research and development, manufacturing, and marketing of animal feed supplement products in Malaysia, China, Singapore, and internationally. It operates through Human Health, Medical Devices and Services, and Loan Financing segments. The company provides veterinary, pharmaceutical, chemical products, animal health, … Read more